Esitanaaf 10 mg (Tablet)

Unit Price: ৳ 11.00 (3 x 10: ৳ 330.00)

Strip Price: ৳ 110.00

Medicine Details

Orally administered selective serotonin reuptake inhibitor (SSRI)
Pure S-enantiomer of the racemic bicyclic phthalate derivative citalopram
At least 100 fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake
No or very low affinity for serotonergic or other receptors including alpha- and beta-adrenergic Dopamine, Histamine, Muscarinic and benzodiazepine receptors

Safety of daily doses above 20 mg has not been demonstrated
Administered as a single daily dose
Usual dosage is 10 mg once daily for major depressive episodes
An initial dose of 5 mg is recommended for panic disorder with or without agoraphobia
Usual dosage is 10 mg once daily for social anxiety disorder
Initial dosage is 10 mg once daily for generalised anxiety disorder
Initial dosage is 10 mg once daily for obsessive-compulsive disorder

SSRI or related antidepressants should not be started until 2 weeks after stopping an MAOI
An MAOI should not be started until at least a week after an SSRI or related antidepressant has been stopped (2 weeks in the case of paroxetine and sertraline, at least 5 weeks in the case of fluoxetine)

Contraindicated in patients with known hypersensitivity to Escitalopram or Citalopram or any of the inactive ingredients of the drug product
Concomitant use of escitalopram in patients taking monoamine oxidase/pimozide is contraindicated

Less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants
Include gastrointestinal effects, anorexia with weight loss or increased appetite and weight gain, hypersensitivity reactions, dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances

When treating a pregnant woman with Escitalopram during the third trimester, the physician should carefully consider the potential risks and benefits of treatment
Excreted in human breast milk
Decision whether to continue or discontinue nursing or Escitalopram therapy should take into account the risk of citalopram exposure for the infant and the benefits Escitalopram treatment for the mother

Should be used with caution in patients with epilepsy, concurrent electroconvulsive therapy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, concomitant use of drugs that increase risk of bleeding, history of bleeding disorders, hepatic and renal impairment

Elderly patients (>65 years of age): Initial dosage is 5 mg once daily
Children and adolescents (<18 years): Esitanaaf should not be used in the treatment of children and adolescents under the age of 18 years
Reduced renal function: Dosage adjustment is not necessary in patients with mild or moderate renal impairment
Reduced hepatic function: An initial dose of 5 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment
Poor metabolizers of CYP2C19: An initial dose of 5 mg daily during the first two weeks of treatment is recommended
When stopping treatment with escitalopram the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of discontinuation symptoms

Symptoms include those related to the central nervous system, gastrointestinal system, and cardiovascular system, as well as electrolyte/fluid balance conditions
There is no specific antidote
Establish and maintain an airway, ensure adequate oxygenation and respiratory function
Gastric lavage and the use of activated charcoal should be considered
ECG monitoring is advised in case of overdose